MicroRNA-345 inhibits metastasis and epithelial-mesenchymal transition of gastric cancer by targeting FOXQ1

被引:46
作者
Feng, Aiwen [1 ]
Yuan, Xiaoming [1 ]
Li, Xiangwei [2 ]
机构
[1] Huaian First Peoples Hosp, Dept Enterochirurg, 6 Beijing Xi Rd, Huaian 223300, Jiangsu, Peoples R China
[2] Huaian First Peoples Hosp, Dept Gastroenterol Surg, Huaian 223300, Jiangsu, Peoples R China
关键词
miR-345; gastric cancer; FOXQ1; metastasis; epithelial-mesenchymal transition; INVASION; PROLIFERATION; BIOGENESIS; EXPRESSION; EMT;
D O I
10.3892/or.2017.6001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
MicroRNAs (miRNAs) are a group of critical players in gastric cancer (GC). Among numerous cancer-related miRNAs, the expression level and functional role of miR-345 in GC has not been investigated. This study showed that miR-345 expression was decreased in GC. Decreased expression level of miR-345 was associated with occurrence of lymph metastasis and advanced TNM stage of GC patients. Patients with low expression level of miR-345 had reduced overall survival (OS) and disease-free survival (DFS). In vitro experiments showed that miR-345 could inhibit the migration and invasion of GC cells. In vivo experiments showed that miR-345 knockdown could promote lung metastasis of GC cells in nude mice. miR-345 was found to prevent the metastasis by inhibiting epithelial-mesenchymal transition (EMT) of GC cells. Furthermore, FOXQ1 was confirmed to be the downstream target of miR-345 in GC cells. Forced expression of FOXQ1 could reverse the inhibitory effects of miR-345 on GC metastasis, while knockdown of FOXQ1 prevented the promoting effects of miR-345 knockdown on GC metastasis. In summary, this study demonstrates miR-345 is a promising biomarker and therapeutic target in GC.
引用
收藏
页码:2752 / 2760
页数:9
相关论文
共 22 条
[1]   MicroRNA functions in animal development and human disease [J].
Alvarez-Garcia, I ;
Miska, EA .
DEVELOPMENT, 2005, 132 (21) :4653-4662
[2]   MicroRNAs: Novel Biomarkers for Human Cancer [J].
Bartels, Claudine L. ;
Tsongalis, Gregory J. .
CLINICAL CHEMISTRY, 2009, 55 (04) :623-631
[3]  
Carcas Lauren Peirce, 2014, J Carcinog, V13, P14, DOI 10.4103/1477-3163.146506
[4]  
Chen LM, 2015, INT J CLIN EXP MED, V8, P20971
[5]   MiR-345 suppresses proliferation, migration and invasion by targeting Smad1 in human prostate cancer [J].
Chen, Qi-guang ;
Zhou, Wei ;
Han, Tao ;
Du, Shu-qi ;
Li, Zhen-hua ;
Zhang, Zhe ;
Shan, Guang-yi ;
Kong, Chui-ze .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2016, 142 (01) :213-224
[6]   Epidemiology of gastric cancer [J].
Crew, Katherine D. ;
Neugut, Alfred I. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (03) :354-362
[7]   MicroRNA biogenesis and cancer [J].
Gregory, RI ;
Shiekhattar, R .
CANCER RESEARCH, 2005, 65 (09) :3509-3512
[8]   Regulation of microRNA biogenesis [J].
Ha, Minju ;
Kim, V. Narry .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2014, 15 (08) :509-524
[9]  
Hampton T, 2007, JAMA-J AM MED ASSOC, V298, P1998
[10]   Increased expression of FOXQ1 is a prognostic marker for patients with gastric cancer [J].
Liang, Shu-Hui ;
Yan, Xi-Zhang ;
Wang, Biao-Luo ;
Jin, Hai-Feng ;
Yao, Li-Ping ;
Li, Ya-Ni ;
Chen, Min ;
Nie, Yong-Zhan ;
Wang, Xin ;
Guo, Xue-Gang ;
Wu, Kai-Chun ;
Ding, Jie ;
Fan, Dai-Ming .
TUMOR BIOLOGY, 2013, 34 (05) :2605-2609